➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
Dow
Boehringer Ingelheim
McKinsey

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENCORAFENIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Encorafenib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01777776 Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated Array BioPharma Phase 1/Phase 2 2013-07-01 To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
NCT01820364 LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Completed Array BioPharma Phase 2 2013-11-01 The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
NCT02109653 Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC Withdrawn Array BioPharma Phase 2 2015-06-01 This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
NCT02263898 Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn National Cancer Institute (NCI) Phase 2 2015-01-01 This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time when tumors become resistant to the drugs.
NCT02263898 Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn Jonsson Comprehensive Cancer Center Phase 2 2015-01-01 This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time when tumors become resistant to the drugs.
NCT02834364 BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Recruiting Array BioPharma Phase 2 2016-06-01 Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).
NCT02834364 BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Recruiting Coordinating Centre for Clinical Trials Heidelberg Phase 2 2016-06-01 Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Encorafenib

Condition Name

Condition Name for Encorafenib
Intervention Trials
Metastatic Melanoma 3
BRAF V600E 2
Metastatic Rectal Adenocarcinoma 2
Stage IV Melanoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Encorafenib
Intervention Trials
Melanoma 12
Colorectal Neoplasms 4
Lung Neoplasms 3
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Encorafenib

Trials by Country

Trials by Country for Encorafenib
Location Trials
United States 39
Spain 8
Germany 3
Netherlands 3
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Encorafenib
Location Trials
California 6
Maryland 4
Tennessee 3
New York 3
Colorado 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Encorafenib

Clinical Trial Phase

Clinical Trial Phase for Encorafenib
Clinical Trial Phase Trials
Phase 3 1
Phase 2 19
Phase 1/Phase 2 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Encorafenib
Clinical Trial Phase Trials
Not yet recruiting 17
Recruiting 6
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Encorafenib

Sponsor Name

Sponsor Name for Encorafenib
Sponsor Trials
Array BioPharma 13
National Cancer Institute (NCI) 9
Pierre Fabre Medicament 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Encorafenib
Sponsor Trials
Other 22
Industry 20
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Merck
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.